In all three patients, TRMA was confirmed by direct sequencing of the SLC19A2 gene that revealed a novel missense homozygous mutation c.382 G>A (p.E128K). The gene discussed is SLC19A2; the disease is thiamine-responsive megaloblastic anemia syndrome.